B Cell Leukemia Clinical Trials

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
N
CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
Recruiting
  • Acute Lymphoid Leukemia
  • +4 more
  • CD19/CD22 CAR T-Cells
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
2022-04-07
Apr 7, 2022
H
CD19/CD20 Dual-CAR-T in B-cell Leukemia Patients - 2022
Completed
  • B-cell Leukemia
  • CD19/CD20 Dual-CAR-T cells
  • Sanhe, Hebei, China
    Hebei Yanda Ludaopei Hospital
2022-03-06
Mar 6, 2022
U
CD19-targeting, 3rd Generation CAR T Cells for Refractory B Cells Malignancy - 2021
Completed
  • B-cell Leukemia
  • B-Cell Lymphoma
  • CAR T cells
  • Uppsala, Sweden
    Uppsala University Hospital, Dept of Oncology
2021-10-14
Oct 14, 2021
Z
Interleukin-2 Following 4SCAR19/22 T Cells Targeting Refractory and/or Recurrent B Cell Malignancies
Suspended
  • B-Cell Leukemia
  • B-Cell Lymphoma
  • Guangzhou, Guangdong, China
    Zhujiang Hospital of Southern Medical University
2021-08-09
Aug 9, 2021
S
CAR-T Immunotherapy Targeting CD19- ALL
Recruiting
  • B-cell Leukemia
  • 4SCAR-CD22/CD123/CD38/CD10/CD20/TSLPR
  • Guangzhou, Guangdong, China
  • +2 more
2019-09-18
Sep 18, 2019
H
CAR T Cells for Refractory B Cell Malignancy
Unknown status
  • B-Cell Leukemia
  • B-Cell Lymphoma
  • Autologous CD19-targeting CAR T cells
  • Shijiazhuang, Hebei, China
    No.2 Hospital of Hebei Medical University
2017-04-27
Apr 27, 2017
S
Phase 2 Fludarabine, Cytoxan and FCCAM <Alemtuzumab> in Untreated B-Cell Chronic Lymphocytic Leukemia - 2011
Completed
Has Results
  • Leukemia
  • +3 more
  • Stanford, California
    Stanford University School of Medicine
2014-09-25
Sep 25, 2014
P
Study of the Safety and Tolerability of PCI-32765 in Patients With Recurrent B Cell Lymphoma - 2012
Completed
  • B-Cell Lymphoma
  • B-Cell Leukemia
  • Palo Alto, California
  • +8 more
2013-05-21
May 21, 2013